Civica Rx COO McCoy To Step Into CEO Role From 1 June
Current President And CEO VanTrieste To Retire But Retain Seat On Board
Civica Rx’s chief operating officer Ned McCoy is to step up as CEO, ahead of the company’s landmark manufacturing facility commencing operations in early 2024.
You may also be interested in...
Civica has selected Profil as its clinical partner as it develops its affordable range of biosimilar insulins, and has also added pharmacy benefit manager EmsanaRx to its generic CivicaScript network.
Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.
CDMO Catalent and US health insurance giant Anthem have joined up with non-profit Civica’s new outpatient-focused generics business arm, CivicaScript, with plans to begin rolling out products as early as next year.